LYL331 / Lyell Immunopharma - LARVOL DELTA

Increased potency and functional persistence in vitro of a next-generation NY-ESO-1-specific TCR therapy incorporating Gen-RTM genetic reprogramming technology (SITC 2022) - "Background Letetresgene autoleucel (lete-cel; GSK3377794) is a first-generation (1st gen) NY-ESO-1-specific T-cell receptor (TCR) therapy with demonstrated clinical activity in solid tumors. Conclusions In addition to supporting the hypothesis that genetic reprogramming with Gen-R technology can delay the onset of exhaustion and improve the long-term durable functions of LYL331, these data show that c-Jun overexpression can provide immediate benefits to the NY-ESO-1-specific TCR therapy during primary stimulation in vitro . Based on these promising pre-clinical data, LYL331 may have the potential to improve clinical responses in patients with solid tumor malignancies."

IO biomarker • Preclinical • Oncology • Solid Tumor • CD4 • CD8 • CTAG1B • ENTPD1 • IFNG • JUN • PD-1 • TIGIT

GSK axes Lyell cell therapy, passes programs to Adaptimmune (FierceBiotech) - "GSK has axed its NY-ESO-1 T-cell receptor (TCR) pact with Lyell Immunopharma, with the Big Pharma transferring the program to Adaptimmune. It means that months after stopping enrollment in a study of its first-generation NY-ESO-1 candidate, GSK has walked away from a $1 billion-plus pact with Lyell that could have delivered enhanced successors....Over the summer, Lyell warned the partnership faced 'new uncertainty' because GSK had stopped enrollment in a clinical trial of a first-generation NY-ESO-1 candidate after it delivered lackluster data....In a Securities and Exchange Commission filing, Lyell said its understanding is that the strategic review sparked by the lete-cel data led to GSK’s decision to terminate the partnered programs, LYL132 and LYL331. The winner from this decision appears to be Adaptimmune, which announced in a separate release today that it had gained possession of NY-ESO and another TCR T-cell program called PRAME."

Licensing / partnership • Oncology

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) - "Lyell Immunopharma....announced today that five abstracts highlighting preclinical data on its product candidates and new genetic and epigenetic reprogramming technologies were accepted for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)....The combination of these two genetic reprogramming technologies is being incorporated in Lyell’s new product candidate, LYL119, a second generation investigational ROR1 targeting CAR T-cell therapy....Two presentations will feature preclinical data from LYL845...designed to create products with higher proportions of stem-like T cells. Lyell will also present preclinical data from its new genetic reprogramming technology designed to further limit T cell exhaustion, as well as data on its new epigenetic reprogramming technology, Stim-R™, designed to generate a more potent T cell product by controlling delivery of activation molecules during T cell production."

Preclinical • Oncology

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights (GlobeNewswire) - "Full Year 2021, Recent Highlights, and Upcoming Milestones: (i) On track to submit an IND in the second half of 2022 for LYL845, a tumor infiltrating lymphocyte (TIL) therapy; (ii) GSK has communicated to Lyell that due to updated manufacturing timing, the IND for LYL331 is likely to be submitted in late 2022 / early 2023. LYL331 is a TCR therapy for patients with solid tumors expressing NY-ESO-1."

IND • Oncology • Solid Tumor